Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12797019 | 0.89 | MAOB (0.48) | CES1MAOBCYP2A6MAOAESR1 | |
| SCHEMBL6615621 | 0.78 | CES1 (0.48) | CES1MAOBCYP2A6MAOAPDPK1 | |
| SCHEMBL2063981 | 0.77 | ESR1 (0.43) | CES1MAOBESR1TDP1L3MBTL1 | |
| SCHEMBL2063983 | 0.77 | ESR1 (0.43) | CES1MAOBESR1TDP1L3MBTL1 | |
| SCHEMBL990643 | 0.75 | MEN1 (0.42) | MAOBESR1SMN1; SMN2CYP19A1PKM | |
| SCHEMBL29952458 | 0.73 | ESR1 (0.54) | CES1MAOBCYP2A6MAOAESR1 | |
| SCHEMBL2063760 | 0.73 | ESR1 (0.54) | CES1MAOBCYP2A6MAOAESR1 | |
| SCHEMBL13692106 | 0.73 | MAOA (0.47) | CES1MAOBMAOASRD5A2KDM4E | |
| Dihydrophenanthrene SCHEMBL30297028 | 0.68 | CES1 (0.68) | CES1MAOBCYP2A6MAOAPDPK1 | |
| Dihydrophenanthrene SCHEMBL29404495 | 0.68 | CES1 (0.68) | CES1MAOBCYP2A6MAOAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-8148384-B2 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; ischemia reperfusion injury, inflammatory disease, retroviral infections, ischemia reperfusion injury, myocardial infarction | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2008082840-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082839-A2 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161559-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-4797414-A | Naphthothiophene derivatives and their use as respiratory enhancing agents | ZYMA SA (CH) | 1989-01-10 | — | — | US | disclosed |
| EP-0193493-A2 | Tricyclic thieno derivatives, their preparation and pharmaceutical compositions containing them | Zyma SA (CH) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPN1, CAPNS1, CAPN2 | CES1 656/4885MAOB 3959/4885CYP2A6 4143/4885 |
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | PIM1, PIM2, PIM3 | CES1 3102/4885MAOB 3412/4885CYP2A6 4141/4885 |
| US-20080161559-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | CES1 2565/4885MAOB 3361/4885CYP2A6 4144/4885 |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | CES1 2565/4885MAOB 3361/4885CYP2A6 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.